Goofice (elobixibat) / Ipsen 
Welcome,         Profile    Billing    Logout  
 2 Diseases   4 Trials   4 Trials   151 News 


123»
  • ||||||||||  Journal:  Structure-Activity Relationships and Target Selectivity of Phenylsulfonylamino-Benzanilide Inhibitors Based on S1647 at the SLC10 Carriers ASBT, NTCP, and SOAT. (Pubmed Central) -  Nov 14, 2024   
    The peptide drug bulevirtide blocks binding of the hepatitis B and D viruses to NTCP and thereby inhibits the virus's entry into hepatocytes...The present study aimed to comparatively analyze a set of newly synthesized and commercially available S1647 derivatives for their transport inhibition against ASBT, NTCP, and SOAT. Structure-activity relationships were systematically analyzed regarding potency and target specificity to elucidate whether this compound class is worth being further developed in preclinical studies for pharmacological ASBT, NTCP, and/or SOAT inhibition.
  • ||||||||||  Goofice (elobixibat) / Ipsen
    Phase classification:  Study of A3309 in Patients With Dyslipidemia (clinicaltrials.gov) -  Mar 7, 2024   
    P2,  N=36, Completed, 
    Elobixibat reduced the degree of straining during defecation, and improved the lipid profile in HF patients with chronic constipation. Phase classification: P2a --> P2
  • ||||||||||  Goofice (elobixibat) / Eisai, Mochida, Ipsen
    Preclinical, Journal:  Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis. (Pubmed Central) -  Nov 27, 2023   
    Elobixibat suppressed tumor growth by inhibiting bile acid reabsorption, and decreasing total bile acid and primary bile acid levels in the serum and liver. Additionally, the presence of bile acids in the colon may have led to a significant reduction in the proportion of gram-positive bacteria, potentially resulting in decreased secondary bile acid synthesis.
  • ||||||||||  Goofice (elobixibat) / Albireo, Eisai, Mochida
    3270 AGA Constipation and Other Functional Colonic Syndromes (W190b - McCormick Place) -  Mar 23, 2023 - Abstract #DDW2023DDW_2404;    
    The effect was more obvious in older women with a history of CC treatment. Learning Objectives: Understand the pathogenesis of chronic constipation after spinal cord injury , Understand a new system for classifying constipation, Describe the effects of elobixibat, a vibrating capsule, and vagal nerve stimulation in chronic constipation
  • ||||||||||  Goofice (elobixibat) / Eisai, Mochida, Ipsen
    Trial completion date, Trial termination, Trial primary completion date:  Elobixibat for Chronic Constipation Without Defecation Desire (clinicaltrials.gov) -  Mar 9, 2023   
    P4,  N=40, Terminated, 
    Learning Objectives: Understand the pathogenesis of chronic constipation after spinal cord injury , Understand a new system for classifying constipation, Describe the effects of elobixibat, a vibrating capsule, and vagal nerve stimulation in chronic constipation Trial completion date: Mar 2026 --> Mar 2023 | Recruiting --> Terminated | Trial primary completion date: Mar 2025 --> Mar 2023; Personal reason
  • ||||||||||  Goofice (elobixibat) / Eisai, Mochida, Ipsen
    Trial primary completion date:  TANK-27: Long-term Elobixibat for Chronic Constipation (clinicaltrials.gov) -  Jan 5, 2023   
    P4,  N=100, Recruiting, 
    885 Trial primary completion date: Nov 2022 --> Jun 2023
  • ||||||||||  Journal:  Pharmacotherapeutic advances for chronic idiopathic constipation in adults. (Pubmed Central) -  Nov 22, 2022   
    In addition, relamorelin, a ghrelin agonist, seems promising for accelerating colonic transit...On the other hand, the experience with these new agents is still limited, especially for long-term treatment. Another important point is that these new treatments for chronic idiopathic constipation are not available worldwide and their use could be somewhat limited by their still relatively high cost.
  • ||||||||||  Goofice (elobixibat) / Eisai, Mochida, Ipsen
    Enrollment open, Trial completion date:  R-LODD: Elobixibat for Chronic Constipation Without Defecation Desire (clinicaltrials.gov) -  Mar 22, 2022   
    P4,  N=40, Recruiting, 
    Additionally, we discuss the important features and studies for bisacodyl to understand its peculiar characteristics and guide its use in clinical practice, but also stimulate research on open questions. Not yet recruiting --> Recruiting | Trial completion date: Sep 2022 --> Mar 2023
  • ||||||||||  elobixibat (A3309) / Albireo, Ajinomoto, Ferring
    Journal:  Data for evaluating mine roof stability via acoustic impact. (Pubmed Central) -  Feb 12, 2022   
    This paper presents a dataset of a 3309 acoustic recordings of such impacts, labelled as by an expert miner as either drummy or tight. Data was recorded from a number of sites within 5 different underground mines, all potash mines in the Canadian province of Saskatchewan.
  • ||||||||||  Goofice (elobixibat) / Eisai, Mochida, Ipsen
    Enrollment open, Trial completion date, Trial primary completion date:  TANK-27: Long-term Elobixibat for Chronic Constipation (clinicaltrials.gov) -  Nov 16, 2021   
    P4,  N=100, Recruiting, 
    Our direct and indirect meta-analyses revealed that the new CIC medications available in Japan have equal efficacy but that elobixibat and lubiprostone are highly likely to be more efficacious. Not yet recruiting --> Recruiting | Trial completion date: Dec 2022 --> Nov 2023 | Trial primary completion date: May 2022 --> Nov 2022
  • ||||||||||  Clinical, Review, Journal:  Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options. (Pubmed Central) -  Oct 31, 2021   
    Among emerging agents, prucalopride, a prokinetic agent, is recommended as a second-line treatment in refractory CIC patients. In addition, the secretagogues linaclotide and plecanatide and the bile acid transported inhibitor elobixibat can be effective in patients not responsive to a second-line therapeutic regimen, although they are not worldwide commercially available.
  • ||||||||||  elobixibat (A3309) / Albireo, Ajinomoto, Ferring, Resolor (prucalopride) / J&J, Takeda, Amitiza (lubiprostone) / Takeda, Mallinckrodt
    Clinical, Review, Journal:  Medical Management of Constipation in Elderly Patients: Systematic Review. (Pubmed Central) -  Oct 14, 2021   
    Psyllium, calcium polycarbophil, lactulose syrup, lactitol, polyethylene glycol, magnesium hydroxide, stimulant laxative with or without fiber, and other medications were more effective than placebo in elderly constipation patients in short-term...However, the quality of included studies was not high and most of studies was conducted in a small number of patients. Among these laxatives, polyethylene glycol seems to be safe and effective in long-term use of about 6 months in elderly patients.
  • ||||||||||  Goofice (elobixibat) / Eisai, Mochida, Ipsen
    Trial initiation date:  TANK-27: Long-term Elobixibat for Chronic Constipation (clinicaltrials.gov) -  Aug 25, 2021   
    P4,  N=100, Not yet recruiting, 
    Among these laxatives, polyethylene glycol seems to be safe and effective in long-term use of about 6 months in elderly patients. Initiation date: May 2021 --> Sep 2021
  • ||||||||||  elobixibat (A3309) / Albireo, Ajinomoto, Ferring
    Journal:  Letter: elobixibatting for the long run-authors' reply. (Pubmed Central) -  Apr 2, 2021   
    Trial completion date: Jun 2021 --> Oct 2021 | Trial primary completion date: Apr 2021 --> Jul 2021 No abstract available